Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1590/S1806-37562017000000436 http://scihub22266oqcxt.onion/10.1590/S1806-37562017000000436 C6044661!6044661!29791557     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Bras+Pneumol 2018 ; 44 (2): 153-60 Nephropedia Template TP {{tp|p=29791557|t=2018. New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis |pdf=|usr=}}{{29791557}} gab.com Text New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis JO: J Bras Pneumol http://www.kidney.de/pget.php?&tw=1&pmid=29791557 #FOAvip Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the ?white plague?, and promising results are being reported. Twit Text FOAVip New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis ????J Bras Pneumol http://www.kidney.de/pget.php?&tw=1&pmid=29791557 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29791557 #FOAvip English Wikipedia <ref>{{Cite pmid|29791557}}</ref> New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis #MMPMID29791557 Silva DR; Dalcolmo M; Tiberi S; Arbex MA; Munoz-Torrico M; Duarte R; D?Ambrosio L; Visca D; Rendon A; Gaga M; Zumla A; Migliori GB J Bras Pneumol 2018[Mar]; 44 (2): 153-60 PMID29791557show ga Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the ?white plague?, and promising results are being reported. äNew and repurposed drugs to treat multidrug- and extensively drug-resi(epmc).pdf DeepDyve Pubget Overpricing